4D Molecular Therapeutics (FDMT) Equity Ratio: 2019-2025
Historic Equity Ratio for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to 0.87.
- 4D Molecular Therapeutics' Equity Ratio fell 4.93% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 4.93%. This contributed to the annual value of 0.91 for FY2024, which is 0.61% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Equity Ratio stood at 0.87, which was down 2.07% from 0.89 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Equity Ratio peaked at 0.95 during Q1 2024, and registered a low of 0.87 during Q3 2025.
- In the last 3 years, 4D Molecular Therapeutics' Equity Ratio had a median value of 0.91 in 2024 and averaged 0.91.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Equity Ratio grew by 6.43% in 2024, and later declined by 6.34% in 2025.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Equity Ratio stood at 0.90 in 2021, then dropped by 2.13% to 0.88 in 2022, then rose by 2.51% to 0.91 in 2023, then rose by 0.61% to 0.91 in 2024, then dropped by 4.93% to 0.87 in 2025.
- Its Equity Ratio was 0.87 in Q3 2025, compared to 0.89 in Q2 2025 and 0.91 in Q1 2025.